Company Profile
TScan Therapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- TCRX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.76 USD (-2.15%)
Close
Last updated: August 6, 2026
64M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, TCRX closed down 2.15% at $0.7632. No new same-company headline was identified in the current news window.
Company overview
Business overview
TScan Therapeutics is a cell-therapy company focused on T-cell receptor therapies for cancer. Its platform aims to create engineered T cells that can recognize tumor-specific targets.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, TScan sits in advanced cell therapy.
Business Model Characteristics
The company depends on clinical validation, manufacturing execution, and the ability to develop a differentiated TCR platform.
Position Within the Biotechnology Landscape
TScan is a high-catalyst cell-therapy name whose stock is highly sensitive to translational progress.
Future catalysts
TScan’s catalysts are TCR-engineered cell therapy data and any update that shows the platform can handle solid tumors as well as hematologic disease. The stock will move if the clinical story keeps improving.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of TScan Therapeutics, Inc. (TCRX)?
TScan Therapeutics, Inc. (TCRX) most recently closed at 0.76 USD, a -2.15% move versus the previous session.
What is the market cap of TScan Therapeutics, Inc. (TCRX)?
TScan Therapeutics, Inc. currently has a market capitalization of 64M USD on BioPharmSignal.
What does TScan Therapeutics, Inc. do?
TScan Therapeutics is a cell-therapy company focused on T-cell receptor therapies for cancer. Its platform aims to create engineered T cells that can recognize tumor-specific targets.
On which exchange is TCRX stock listed?
TScan Therapeutics, Inc. (TCRX) is associated with NASDAQ, United States, Biopharma.
What is TScan?
TScan’s catalysts are TCR-engineered cell therapy data and any update that shows the platform can handle solid tumors as well as hematologic disease.
Which conditions is TScan Therapeutics, Inc. targeting with TScan?
TScan Therapeutics, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does TScan Therapeutics, Inc. describe recent progress with TScan?
TScan’s catalysts are TCR-engineered cell therapy data and any update that shows the platform can handle solid tumors as well as hematologic disease.
What is Therapeutics?
TScan Therapeutics is a cell-therapy company focused on T-cell receptor therapies for cancer.